Cover Image

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística

Show other versions (1)

Saved in:

Bibliographic Details
Main Author:	Paula Del Río Ortega (Author)
Format:	Book
Published:	Fundación Pharmaceutical Care España, 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022)

USO DE EXACAFTOR/ TEZACAFTOR /IVACAFTOR EN PACIENTES CON FIBROSIS QUÍSTICA POST-TRASPLANTE PULMONAR
by: Pablo Jorquera Pinto
Published: (2023)

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
by: Shiferaw D, et al.
Published: (2019)

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
by: L. Gómez-Ganda, et al.
Published: (2024)

Efectividad de ivacaftor en vida real en niños con fibrosis quística y mutación G551D
by: David Gomez-Pastrana, et al.
Published: (2019)

Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]
by: Shiferaw D, et al.
Published: (2019)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
by: Linus Piehler, et al.
Published: (2023)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor
by: Payal Patel, et al.
Published: (2023)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023)

Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor
by: Varun Garg, et al.
Published: (2019)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
by: Eva Choong, et al.
Published: (2022)

Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
by: Marika Comegna, et al.
Published: (2021)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
by: Renate Kos, et al.
Published: (2022)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
by: Mafalda Bacalhau, et al.
Published: (2023)

Resolution of long standing hypergammaglobulinemic purpura of Waldenström after initiating treatment for cystic fibrosis with Elexacaftor-Tezacaftor-Ivacaftor
by: Kimberly Tantuco, MD, et al.
Published: (2024)

Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study
by: Libor Fila, et al.
Published: (2023)

Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy
by: Frauke Stanke, et al.
Published: (2023)

Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor
by: Wolfgang Gruber, et al.
Published: (2024)

Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together
by: Rachel Kinuani, et al.
Published: (2024)

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity
by: Katharina Schütz, et al.
Published: (2023)

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
by: Jochen G. Mainz, et al.
Published: (2022)

Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study
by: Insa Korten, et al.
Published: (2022)

Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis
by: Rebecca H. Goldberg, BS, et al.
Published: (2021)

Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats
by: Nicole Reyne, et al.
Published: (2024)

A rapid RP-HPLC method for the simultaneous estimation of Ivacaftor and Tezacaftor and in silico study of their metabolitic products
by: Madhuri Donakonda, et al.
Published: (2021)

Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study
by: Giuseppe Migliorisi, et al.
Published: (2022)

Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis
by: Wenye Xu, et al.
Published: (2023)

Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study
by: Sabine Dettmer, et al.
Published: (2023)

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
by: Jochen G. Mainz, et al.
Published: (2023)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
by: Argyri Petrocheilou, et al.
Published: (2020)

Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series
by: Hisham Ibrahim, et al.
Published: (2023)

Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis
by: Michael P. Coughlin, et al.
Published: (2024)

Corrigendum: Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats
by: Nicole Reyne, et al.
Published: (2024)

Lung transplant list withdrawal in a liver transplant patient thanks to elexacaftor-tezacaftor-ivacaftor: a case report
by: Arianna Traunero, et al.
Published: (2024)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
by: O’Reilly R, et al.
Published: (2013)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes
by: Francis Christian MD, et al.
Published: (2019)

Acne vulgaris in a 22‐year‐old cystic fibrosis patient treated with Elexacaftor‐Tezacaftor‐Ivacaftor and good clinical response to isotretinoin-A case report
by: Isabelle Pfeiffer, et al.
Published: (2024)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
by: Connett GJ
Published: (2019)

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
by: Patrick O. Hanafin, et al.
Published: (2021)